5COMPSTON JE,SEEMAN E. Compliance with osteoporosis therapy is the weakest link[ J]. Lancet,2006,368(9540) :973 -974.
6SIRIS ES, HARRIS ST, ROSEN CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women : relationship to vertebral and nonvertebral fractures from 2 US claims databases[J]. Mayo Clin Proc,2006, 81 (8) :1013 - 1022.
7BLACK DM,DELMAS PD,EASTELL R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[ J]. N Engl Med,2007,356(18) :1809 - 1822.
8LYLES KW, COLON-EMERIC CS, MAGAZINER JS,et al. Zoledronic acid and clinical fractures and mortality after hip fracture [J].N Engl J Med, 2007,357(18) :1799 - 1809.
9DUNFORD JE, THOMPSON K, COXON FP,et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates [ J ]. J Pharmacol Exp Ther, 2001,296 ( 2 ) : 235 - 242.
